Table 1 Patient characteristics
Characteristic | Capecitabine (n = 52), n (%) | 5-FU (n = 46), n (%) | p- value | |
|---|---|---|---|---|
Gender | Male | 32 (61.5) | 31(67.4) | 0.173† |
Female | 20 (38.5) | 15 (32.6) | ||
Age (years) | Median (range) | 63 (36–77) | 66 (41–80) | 0.126‡ |
Mean ± SE | 62.1 ± 1.3 | 65.0 ± 1.4 | ||
<65 | 31 (59.6) | 19 (41.3) | 0.105† | |
≥65 | 21 (40.4) | 27 (58.7) | ||
Tumor location | Head | 30 (57.7) | 30 (65.2) | 0.445† |
Body/tail | 22 (42.3) | 16 (34.8) | ||
Tumor size* (cm) | Median (range) | 3.8 (2.4–7.4) | 3.9 (2.5–10) | 0.297‡ |
Mean ± SE | 4.0 ± 0.1 | 4.3 ± 0.2 | ||
<4 | 28 (53.8) | 23 (50) | 0.840‡ | |
≥4 | 24 (46.2) | 23 (50) | ||
Histological differentiation | Well/moderate | 13 (25) | 12 (26.1) | 0.617† |
Poor | 2 (3.9) | 4 (8.7) | ||
Not specified | 37 (71.1) | 20 (65.2) | ||
cN classification | N0 | 32 (61.5) | 25 (54.3) | 0.471† |
N1 | 20 (38.5) | 21 (45.7) | ||
CEA (ng/ mL) | Median (range) | 4.2 (1.2–31.9) | 3.8 (1.0–56.1) | 0.493‡ |
Mean ± SE | 6.4 ± 0.9 | 7.7 ± 1.7 | ||
<5 | 31 (59.6) | 29 (63.0) | 0.836† | |
≥5 | 21 (40.6) | 17 (37.0) | ||
Pretreatment CA 19–9 level (U/mL) | Median (range) | 218.5 (5.0–11445) | 191.5 (5.0–4150) | 0.056‡ |
Mean ± SE | 1179.6 ± 307.3 | 531.1 ± 130.6 | ||
<400 | 29 (55.8) | 31 (67.4) | 0.300† | |
≥400 | 23 (44.2) | 15 (32.6) |